IN RESPONSE: Dr. Johnson is correct in his comments about TMP-SMX as a potential therapeutic agent for MRSA infections. As he points out, however, because the drug is no longer subject to patent protection, it is highly unlikely that a large-scale comparative study of this agent will be undertaken for MRSA infections. In this context, unlike the recently described vancomycin-resistant MRSA (which thus far is very rare), the strains that are resistant to TMP-SMX do occur and, of course, would not be expected to respond to that agent.
Dr. Lindley is also correct: The oral formulation of linezolid is very expensive (in comparison with most other oral antibacterial agents) and for that reason it should not be considered for treatment of routine outpatient infections caused by organisms susceptible to less expensive agents, such as the ␤-lactams and macrolides. However, linezolid becomes relatively less expensive when it is used to allow discontinuation of intravenous therapy with drugs such as vancomycin and to avoid the very expensive costs of hospitalization (or outpatient intravenous therapy).
Robert C. Moellering Jr., MD
Harvard Medical School Beth Israel Deaconess Medical Center Boston, MA 02215
Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

TO THE EDITOR:
The meta-analysis by Highland and colleagues (1) evaluating inhaled corticosteroids in chronic obstructive pulmonary disease (COPD) addresses an important and controversial topic. However, certain methodologic issues may have adversely affected the validity of this analysis.
First, inspection of the authors' Table 2 and forest plot suggests that a study favoring inhaled corticosteroids was incorrectly interpreted and analyzed. All studies included in the analysis reported an absolute improvement with inhaled corticosteroids, resulting in a less negative rate of decline in FEV 1 . Paradoxically, the authors interpreted the treatment effect from Vestbo and associates' study (2) as 3.1 mL/y (accelerated rate of decline) rather than Ϫ3.1 mL/y, suggesting that data from 290 patients (8% of the sample) were analyzed improperly.
Second, the authors excluded the study by Derenne (3) , stating that the data were reported only in abstract form. However, these data have been reported in a peer-reviewed manuscript as part of pooled secondary analysis of data from 3 trials (4).
Finally, Pauwels and coworkers (5) specified that their results were reported as median treatment effects, but Highland and colleagues reported using means and standard errors in their fixedeffects analysis. How was the mean treatment effect for this study determined?
The application of this analysis to clinical practice is also influenced by the debate regarding the importance of spirometric versus clinical outcomes in COPD clinical trials. Inhaled corticosteroids improve symptoms and reduce exacerbations in some patients with COPD, and whether they improve other physiologic outcomes (for example, hyperinflation) is not well understood. Until additional data improve our ability to identify which patients benefit and why, targeted use of inhaled corticosteroids according to consensus recommendations (6) may be the best way of ensuring that patients with moderate to severe COPD are given the opportunity to benefit from these drugs.
E. Rand Sutherland, MD, MPH National Jewish Medical and Research Center
Denver, CO 80206 previous meta-analysis was excluded by our predetermined criteria; this study included patients with asthma. The third study by Derenne (4) was not included in our analysis because the data were reported only in abstract form and could not be extracted from the original abstract. In addition, the author could not be contacted.
We included data from the study by Pauwels and coworkers (5) as mean rather than median values because the variant of the t-test used in meta-analyses is robust to large deviations from normality (6) . In this study, the baseline distributions had very low coefficients of variation in both groups (0.17 and 0.16), suggesting that outliers contributed to the skewness in change from baseline. When a sample from a symmetrical population contains outliers, the sample median is a better estimate of the population mean than the sample mean. We were unable to obtain data from the authors to verify our assumption. We believed it was necessary to include this very large study (1277 patients) in our meta-analysis because it met our inclusion criteria and favored a treatment effect. If we reanalyze our data with this study excluded, however, the overall treatment effect remains nonsignificant (Ϫ4.98 mL/y; P ϭ 0.11). Sensitivity analysis demonstrated that the difference between the actual means and the reported medians would need to be extraordinarily large (more than 2-fold) to change the statistical conclusions of our model.
We made an error in analyzing the treatment effect reported by Vestbo and associates (7) (3.1 mL/y rather than Ϫ3.1 mL/y). This error, however, did not alter the conclusions of our analysis because the effect on our results is minor. Using the corrected value, the overall treatment effect is Ϫ5.31 Ϯ 3.0 mL/y (P ϭ 0.08) as opposed to the originally reported Ϫ5.0 Ϯ 3.2 mL/y (P ϭ 0.11).
Our meta-analysis confirms the Global Initiative for Chronic Obstructive Lung Disease Workshop's opinion that inhaled corticosteroids do not modify the long-term decline in lung function of COPD (8) . We agree with Dr. Sutherland that patient-centered measures of outcome, such as respiratory-related quality of life, are more important than FEV 1 in assessing the value of interventions to improve the well-being of patients with COPD. Pending future investigations, clinicians should not prescribe inhaled corticosteroids with the belief that this therapy will attenuate the decline in FEV 1 .
Kristin B. Highland, MD Medical University of South Carolina Charleston, SC 29425
Subclinical Thyroid Dysfunction and the Heart TO THE EDITOR: Biondi and colleagues should be congratulated for their excellent review (1) on effects of subclinical thyroid dysfunction on the heart. In their discussion of atrial fibrillation in subclinical hyperthyroidism, they mentioned 2 studies of older people that have addressed this topic (2, 3). Tenerz and coworkers (2) examined 40 patients with subclinical hyperthyroidism and found 8 cases of atrial fibrillation; 3 additional patients developed atrial fibrillation during the 2-year follow-up. The rate of atrial fibrillation was 28% in patients with subclinical hyperthyroidism and 10% in matched euthyroid patients.
To determine the frequency of atrial fibrillation during a 10-year follow-up period, Sawin and associates (3) studied 2007 participants in the Framingham Study who were 60 years of age and did not have atrial fibrillation. The study sample was composed of 61 persons with low serum thyroid-stimulating hormone (TSH) concentrations(Յ0.1 mU/L), 187 persons with slightly low levels (Ͼ0.1 to 0.4 mU/L), 1576 persons with normal levels (Ͼ0.4 to 5.0 mU/L), and 183 persons with high levels (Ͼ5.0 mU/L). Thus, 248 persons had low serum TSH concentrations and 187 persons had values that may represent most patients with subclinical hyperthyroidism. Biondi and colleagues erred when they stated that Sawin and associates (3) investigated 2007 patients with low TSH levels due to exogenous or endogenous factors. Moreover, after exclusion of patients with low serum TSH concentrations (Յ0.1 mU/L), the remaining participants, who had only slightly low serum TSH concentrations (as do most patients with subclinical hyperthyroidism), had only a moderately higher risk for atrial fibrillation than those with normal concentrations (relative risk, 1.6). This result barely reached statistical significance, primarily because few patients were included in the analysis.
The studies by Tenerz and Sawin and associates together included 227 patients with subclinical hyperthyroidism. Biondi and colleagues did not refer to a recent study by our group (4) that examined 23 638 persons, including 613 patients with subclinical hyperthyroidism (defined as low serum TSH levels [Ͻ0.4 mU/L] and normal levels of free triiodothyronine and free thyroxine concentrations). After adjustment for age and for the presence of other known risk factors, including hypertension and left ventricular hypertrophy and underlying structural heart disease, we found an almost 3-fold higher relative risk for atrial fibrillation in patients with subclinical hyperthyroidism compared with those with normal concentrations of serum TSH (4) .
The addition of a study with findings based on data from a In a recent review, Biondi and colleagues (1) suggested that persistent subclinical hypothyroidism (TSH level Ͼ4.0 mU/L) should be treated and that the benefits of treatment include "possible reduced risk for atherosclerosis and coronary artery disease." The authors stated, "Striking evidence of a higher risk for atherosclerotic cardiovascular death in patients with subclinical hypothyroidism emerged from the Rotterdam study." However, the Rotterdam study did not report cardiovascular deaths (2) . In that study, the baseline prevalence of myocardial infarction (defined by self-report, electrocardiography, or both) and radiographic aortic calcification was increased in subclinically hypothyroid women compared with euthyroid women, but the incidence of first myocardial infarction was not significantly increased in subclinically hypothyroid women after an average of 4.6 years of follow-up (1036 women were followed, but statistical power was limited because events were infrequent) (2). Furthermore, Biondi and colleagues reported that "Perk and O'Neill, using sequential coronary angiography, found that appropriate thyroid hormone replacement therapy prevented progression of angiographic coronary artery disease." This conclusion was based on data from 10 patients (3). Moreover, in a 10-year populationbased cohort study of 1191 individuals 60 years of age or older (4), there was no increase in standardized mortality ratios for all causes (standardized mortality ratio, 0.9 [95% CI, 0.6 to 1.3]) or cardiovascular disease (standardized mortality ratio, 0.7 [CI, 0.4 to 1.2]) in those with a TSH level greater than 5.0 mU/L. Furthermore, in women in the Wickham survey (5), elevated serum TSH levels were not associated with increased mortality or development of ischemic heart after 20 years.
In conclusion, clinicians and patients must understand that the reported relationship between subclinical hypothyroidism and atherosclerosis is primarily based on retrospective case-control and cross-sectional analyses. In the absence of controlled trial data, there is currently insufficient evidence to warrant routine prescription of thyroid hormone in all subclinically hypothyroid patients, if the intention is prevention of coronary artery disease. As indicated by Auer and colleagues, their large crosssectional study (1) does have a bearing on our study. Indeed, their findings of a similar relative risk for atrial fibrillation in patients with subclinical hyperthyroidism (serum TSH level Յ0.4 mU/L) and patients with overt hyperthyroidism (serum TSH level Ͻ0.03 mU/L), and an almost 3-fold (95% CI, 1.3-fold to 5.8-fold) higher risk versus euthyroid controls (P Ͻ 0.01), strengthen the concept that thyroid secretion need not increase much for atrial fibrillation to occur and that subclinical hyperthyroidism itself may precipitate atrial fibrillation and associated sequelae, especially in the elderly. We did not cite the study by Auer and colleagues because it was published when our review was at an advanced stage of the revision process. We thank Auer and colleagues for pointing out that only 187 of the 2007 older patients studied by Sawin and associates (2) could strictly be considered as having subclinical hyperthyroidism (serum TSH level Յ0.4 mU/L).
A.M. Sawka, MD
Turning to the observations of Drs. Sawka and Fatourechi, we believe that the literature contains information that may help clinicians manage subclinical hypothyroidism. There is now clear evidence that subclinical hypothyroidism is a mild type of tissue hypothyroidism (3) and that it may progress to overt thyroid failure, especially if associated with positive thyroid autoantibodies (4). Relevant and reversible modifications in lipid metabolism and cardiovascular function have been reported in most clinical investigations of patients with persistent subclinical hypothyroidism treated with L-thyroxine (5) . In this context, until compelling evidence is provided by controlled trials, it seems morally and scientifically justifiable to consider L-thyroxine treatment on a case-by-case basis after careful evaluation of the actual risk for overt thyroid failure and cardiovascular events. However, candidates for treatment should have a favorable cardiovascular condition, a low starting dose of L-thyroxine should be used, and biochemistry should be regularly monitored to avoid overzealous hormonal dosing and iatrogenic disease associated with hyperthyroidism. 
Chemotherapy in Women with Breast Cancer
TO THE EDITOR: Du and colleagues (1) reported that in New Mexico between 1991 and 1997, only 29% of women with a diagnosis of early-stage breast cancer received adjuvant chemotherapy. Their study implied that 71% of women in New Mexico who had this disease were undertreated during this period. The accompanying Editors' Notes state that "many unnecessary deaths could be prevented" if National Institutes of Health (NIH) guidelines are followed. We believe that the study conclusion and the editorial comment are both unwarranted.
The number of patients examined by Du and colleagues perplexes us. Although the authors reported that they screened records on 5101 patients, when we added the numbers of patients from whom information regarding chemotherapy was gleaned as reported in the Methods section, there seem to have been 5947 cases involved. An explanation of this discrepancy would be appreciated.
Of more concern is the confusion that the authors and the editors seemed to have regarding which NIH guidelines were in place during the study period. The guidelines that the editors cited were not issued until 2000 (2) . The Figure in the article showed the percentage of women who received chemotherapy on the basis of the 1990 NIH guidelines (3). Although raw numbers were not given, it would appear from inspection of the Figure that a majority of women younger than 70 years of age whose tumors met the existing NIH guidelines for chemotherapy treatment were, in fact, treated with chemotherapy.
Most of the patients in Du and colleagues' study had stage I disease. Guidelines in place during the study period would not have recommended treatment with chemotherapy for any patients with hormone receptor-positive stage 1 disease and would have recommended chemotherapy only for patients with hormone receptornegative tumors greater than 1.0 cm in size. Similarly, patients who had stage 2 tumors between 2.0 and 3.0 cm, negative lymph nodes, and positive hormone receptors would not have met the 1990 NIH guidelines for treatment with chemotherapy. All of these patients should have been removed from analysis, since lack of chemotherapy treatment in their cases does not constitute a "discrepancy" with the 1990 NIH guidelines.
We agree completely with Du and colleagues' comments in the Discussion section, which questioned whether the information on chemotherapy from the Surveillance, Epidemiology, and End Results (SEER) tumor registries is valid and complete. Given Du and colleagues' own lack of confidence in their data, it is difficult to have confidence in their conclusions. We also concur with Du and colleagues' concerns about the limitations of guidelines and how they can become outdated. In this regard, the recent publication of the largest study of tamoxifen and chemotherapy in postmenopausal patients with node-negative, hormone receptor-positive disease supports treating such patients with tamoxifen alone (4, 5) .
All patients should be offered the best medical care available. As Du and colleagues pointed out, there can be many reasons why individual patients may not be well served with treatment based solely on guidelines. However, for the reasons we cited, Du and colleagues' study did not demonstrate that most patients with earlystage breast cancer in New Mexico between 1991 and 1997 were undertreated according to the 1990 NIH guidelines. Similarly, Du and colleagues' study does not support the inflammatory implication of the editors' comment that "many unnecessary deaths" could have been prevented had New Mexico oncologists treated more patients with chemotherapy in the 1990s. TO THE EDITOR: Du and colleagues (1) used data from the New Mexico SEER tumor registry from 1991 to 1997 to assess use of chemotherapy among women with early-stage breast cancer. They concluded that there is a considerable discrepancy between the NIH Consensus Conference recommendations and community-based practice. However, much of this discrepancy may reflect low ascertainment of chemotherapy by the SEER registries.
Because the National Cancer Institute recognizes that chemotherapy is underreported in SEER data, it funds Patterns of Care (POC) studies, in which SEER registries verify with the treating physicians the chemotherapy provided for a sample of cases. In 1991 and 1995, the SEER registries, including the New Mexico Tumor Registry, conducted a POC study for women with early-stage breast cancer (2, 3). We used cases from the POC data to determine the sensitivity of the SEER data in capturing chemotherapy use. Sensitivity was defined as the number of women in the POC data who had a SEER record of chemotherapy divided by the total number of women identified as receiving chemotherapy from the POC data. Because the sample size from New Mexico alone was small, we used POC data from all registries to obtain stable estimates of sensitivity.
We found that the sensitivity of the SEER chemotherapy data was only 78%. Sensitivity declined by age, from 79% for women younger than 45 years of age to 53% for women 75 years of age and older. For 1991 alone, the sensitivity was only 33% for women age 75 years and older. These estimates of sensitivity are likely to be optimistic because POC studies were conducted in 1991 and 1995, and some registries update their data using the POC data that are unavailable in other years.
We agree that current rates of chemotherapy use for breast cancer are not optimal. However, the estimates provided by Du and colleagues, which relied on SEER data alone, do not provide an accurate measure of this treatment gap, especially for older age groups.
IN RESPONSE: Liebmann and colleagues correctly point out a typo for chemotherapy codes in the Methods section of our article. The numbers of cases for the 7 code categories in 5101 women should be 3574, 129, 21, 1248, 61, 68, and 0, respectively. However, we did not imply that 71% of women with breast cancer were undertreated with chemotherapy. In the 1990 NIH guidelines, adjuvant chemotherapy was not recommended in all women with stage I to IIIA disease. Therefore, it is important to separate cases into 2 groups: 1 group in which chemotherapy was generally recommended, and another group in which chemotherapy was discretionary. In the first group of 2486 women, 1854 were younger than age 70 years; of these, 61.3% received adjuvant chemotherapy. The percentage of women receiving chemotherapy was 77.4% for those younger than 45 years of age, 58.1% for those 55 to 59 years of age, 37.7% for those 60 to 64 years of age, and only 25% for those 65 to 69 years of age, as shown in our Results section. Clearly there is substantial room for improvement in use of adjuvant chemotherapy.
We agree with Liebmann and colleagues that the conclusion in the Editors' Notes was not supported by the study. Because our study did not address whether those who received chemotherapy survived longer than those who did not, it is difficult to conclude that many unnecessary deaths could have been prevented if guidelines were followed.
As we discussed in our article, SEER information on chemotherapy may be incomplete. Harlan and associates provide analyses of the sensitivity of the SEER information on chemotherapy use. Because their estimates were combined for all SEER registries, it is still unknown how their findings could be generalized to our study population, given substantial geographical variations in chemotherapy use (1, 2) . It is also unclear whether the sensitivity of the SEER chemotherapy data varies by tumor stage. The internal validity of chemotherapy data in our study appeared good. For example, among women with stage IIIA disease, 96% of those younger than 45 years of age, 92% of those 45 to 49 years of age, and 94% of those 50 to 54 years of age were recorded as having received adjuvant chemotherapy. Older age is an important, well-known factor for receiving less than definitive therapy (1, 2) . However, what is interesting, and what was one of the key findings in our study, is that there was a marked decreasing pattern of chemotherapy use with age that could be explained in part by age-related decreasing efficacy of chemotherapy (3). This seems unique to women with breast cancer; no decreasing efficacy of chemotherapy with advanced age has been found for men and women with lung and colon cancer (4, 5 : We appreciate that Dr. Liebmann and associates took the trouble to write to us about our Editors' Notes for the article by Du and colleagues. We said that "many unnecessary deaths could probably be prevented by following the National Institutes of Health guidelines." Liebmann and associates' citation of our statement omitted the word "probably," a word that we chose with care to be sure that readers understood that we were making a conjecture rather than a conclusion based on established fact. Our conjecture would have been more informed if we had estimated the number of women who might have benefited from adjuvant therapy, as we have tried to do for this response.
The NIH guidelines in force in 1991 to 1997, the dates of Du and colleagues' study, recommended chemotherapy for women with node-positive tumors or node-negative tumors with poor prognostic features. For our estimate, we confined ourselves to node-positive tumors, since Du and colleagues' study lacked information about the latter group. In the New Mexico study, 1660 women 50 to 69 years of age received a diagnosis of stage I, stage II, or stage IIIA breast cancer between 1991 and 1997 and did not receive adjuvant chemotherapy. The article did not provide the number of node-positive women who did not receive chemotherapy. To provide an upper bound on this number, we assumed that 34% of women who did not receive chemotherapy had node-positive disease, the same proportion as in all women in the New Mexico study (in fact, Ͻ34% of women who did not receive chemotherapy had node-positive disease, as seen in Du and colleagues' Table 2 ). According to this assumption, 564 of the 1660 women who did not receive chemotherapy would have had node-positive disease. According to data from the Early Breast Cancer Trialists' Collaborative Group (1), the absolute gain in 10-year survival was 3% for 50-to 69-year-old women with node-positive disease (46% to 49%). Therefore, the potential gain in 10-year survival from receiving recommended chemotherapy was no more than 17 women. This number is smaller than we supposed when we wrote the Editors' Notes, and we would frame our comment more judiciously now. 
The Editors
A Rash Decision
TO THE EDITOR: It was with great interest and pleasure that we read "A Rash Decision" by Georganna Davis (1), an essay we think was intended to convey the angst and insecurity of the author, a medical student, when evaluating a puzzling patient early in her career and making a diagnosis not shared by her venerated mentor. Although we were able to appreciate and relate to the emotions she evoked, we were left with what we feel was an unintended message. Although the patient seemed to have a very severe tinea infection, the experienced physician preceptor was either too busy to perform a potassium hydroxide wet mount preparation or, more alarmingly, didn't even entertain the diagnosis in a patient with a scaly rash.
In the present climate of managed care and decreasing remuneration, financial pressures may dictate that primary care physicians see more patients and spend less time on issues they feel are not important. Although this is not proven, we fear that primary care providers may not place skin disease high among their priorities when they are asked to perform so many other functions, such as chronic disease management, cancer screening, and prevention of cardiovascular disease and death. An alternative explanation for the preceptor's initial misdiagnosis is the overall poor performance of primary care providers with respect to the diagnosis and treatment of cutaneous disease (2, 3) . This is of great importance since 6% of all outpatient encounters involve some symptom affecting the hair, skin, or nails (4), and most patients are seen by nondermatologists (5). Although we don't know why the preceptor didn't make the correct diagnosis in this case, either of our postulated reasons is both telling and disquieting.
Daniel G. Federman, MD
Veterans Affairs Connecticut Health Care System and Yale University West Haven, CT 06516
Robert S. Kirsner, MD Miami Veterans Affairs Medical Center and University of Miami Miami, FL 33125
Objective: To analyze the relationship between iron variables and glucose tolerance, insulin sensitivity, and ␤-cell function in nondiabetic persons.
Methods: Five hundred thirty-eight nondiabetic participants (202 men, 336 women), were given a 75-g oral glucose tolerance test. The mean age (ϮSD) of participants was 35 Ϯ 11 years, and mean body mass index (ϮSD) was 26.1 Ϯ 5.8 kg/m 2 . Insulin sensitivity (mean glucose infusion rate divided by the mean serum insulin concentration) was measured in 257 persons by using a euglycemichyperinsulinemic clamp, and ␤-cell function (mean plasma C-peptide concentration during the first 10 minutes) was measured in 69 participants by using a square-wave hyperglycemic clamp (glucose level, 10 mmol/L). Participants with clinical or laboratory signs of acute infection or liver disease were excluded. Multivariate linear regression analysis on log-transformed values was used. An institutional review board approved the research, and informed consent was obtained.
Findings: Serum ferritin level was positively correlated with 2-hour glucose concentration and negatively correlated with insulin sensitivity (Figure) . These associations remained statistically significant (P ϭ 0.02 and P ϭ 0.003, respectively) after transferrin saturation, age, sex, body mass index, waist-to-hip ratio, leukocyte count, and C-reactive protein level were included as covariates in a multivariate linear regression analysis. There was no significant correlation between serum ferritin concentration and either estimated (from the oral glucose tolerance test) or measured ␤-cell function (P Ͼ 0.2). Discussion: High serum ferritin level (even high-normal serum ferritin level) is an independent, albeit weak, predictor of poor glucose tolerance. This association seems to be secondary to an association with insulin resistance but not with ␤-cell dysfunction. Mechanisms through which iron causes insulin resistance with ultimate impact on glucose homeostasis probably exist in the liver (4). However, muscle and fat cannot be excluded. Iron is a potent pro-oxidant, and reactive oxygen species have been shown to interfere with insulin signaling at the cellular level (5) . Conversely, insulin resistance may be the cause rather than the consequence of disturbances in iron metabolism, as recently reviewed (6) . Finally, although we adjusted for leukocyte count and C-reactive protein level, we cannot entirely exclude the possibility that serum ferritin level is an additional marker of subclinical inflammation, which itself may be a risk factor for type 2 diabetes mellitus (7).
Nevertheless, in view of the sustained improvement in insulin sensitivity after bloodletting (3), it appears possible that iron overload is a weak but effective etiologic factor in the pathogenesis of insulin resistance and type 2 diabetes. It is quite plausible that the unhealthy diets in affluent western societies contribute to diabetes risk not only through excess fat intake but also through excess iron supply (for example, in meat or in iron-supplemented food). Moreover, the iron overload hypothesis partially explains the reduced risk for diabetes in premenopausal women and vegetarian societies (8) .
Conclusion: It may become advisable to routinely screen for mildly elevated or even high-normal serum ferritin concentrations in the context of glucose intolerance. If prospective and interventional studies confirm an etiologic role of iron overload in the pathogenesis of insulin resistance and type 2 diabetes, reduced dietary iron intake, especially in men and postmenopausal women (9) with additional risk factors for type 2 diabetes, would appear to be a logical consequence. In the future, actively lowering body iron stores may become a tool in preventing type 2 diabetes in selected subgroups. Data were derived from least-square linear regression analyses performed on log-transformed data. For 2-hour glucose concentration in all participants, men, and women, r ϭ 0.08 (P ϭ 0.049), r ϭ 0.32 (P Ͻ 0.001), and r ϭ 0.13 (P ϭ 0.002), respectively. For insulin sensitivity in all participants, men, and women, r ϭ Ϫ0.22 (P Ͻ 0.001), r ϭ Ϫ0.35 (P Ͻ 0.001), and r ϭ Ϫ0.22 (P ϭ 0.02), respectively. Mean serum ferritin concentrations (ϮSE) were 154 Ϯ 9 g/L in men and 46 Ϯ 2 g/L in women (P Ͻ 0.001). To convert serum ferritin concentration from g/dL to g/L, multiply by 10. depend on involvement of the lungs. In patients without pulmonary abnormalities, the 5-year survival rate is 90%, whereas in patients with systemic scleroderma-related pulmonary arterial hypertension, median survival is limited to 1 year (1). Since only a few patients with pulmonary arterial hypertension respond to current medical therapy and the possibility of lung transplantation is limited (2), better treatment options are desirable.
Sildenafil Improved Pulmonary Hypertension and Peripheral
Objective: Recent studies indicated that phosphodiesterase type V inhibitors such as sildenafil are of benefit in patients with pulmonary arterial hypertension (3) (4) (5) (6) (7) (8) . Effects on systemic sclerodermarelated pulmonary arterial hypertension, prognostic markers, and peripheral blood flow have not been reported.
Case Report: We examined a 65-year-old woman with lung fibrosis associated with SCL70-positive systemic scleroderma and severe pulmonary arterial hypertension (mean pulmonary arterial pressure, 50 mm Hg) who developed global respiratory insufficiency and was in World Health Organization functional class IV. Clinical symptoms included dyspnea at rest, right-heart failure, and severe Raynaud phenomenon.
The patient's previous treatment included O 2 supplementation, corticosteroids, azathioprine, and calcium-channel blockers. Additional therapy with inhaled or oral prostanoids (iloprost or beraprost, respectively) and the endothelin receptor antagonist bosentan was unsuccessful or was discontinued because of side effects (mucositis, vomiting). The patient was rejected for lung transplantation because of her age and because of the systemic nature of scleroderma. Because no other treatment options were available, oral sildenafil, 50 mg 4 times per day, was initiated and had the following effects.
First, right-heart catheterization showed that sildenafil reduced systolic and mean pulmonary arterial pressure by 23% and 28%, respectively (Figure, (Figure, part B) .
Second, plasma levels of brain natriuretic peptide, which are a prognostic indicator in patients with right-heart failure, decreased from 9709 ng/L to 445 ng/L within 4 months (Figure, part C) , indicating a significant decline in right ventricular overload. Third, sildenafil improved the Raynaud phenomenon related to systemic scleroderma. Severity and frequency of acrocyanosis decreased with sildenafil treatment, and laser flux Doppler demonstrated improved perfusion of the fingertips at room temperature and peripheral blood-flow reserve at 40°C (Figure, part D) .
Discussion: In this patient, sildenafil had beneficial effects on pulmonary hemodynamic variables, similar to findings in other reports of patients with pulmonary arterial hypertension (3) (4) (5) (6) (7) (8) . Our findings further extend the therapeutic potential of phosphodiesterase type V inhibition to pulmonary arterial hypertension related to systemic scleroderma. Furthermore, we demonstrated that sildenafil significantly increased peripheral blood flow and decreased the severity and frequency of the Raynaud syndrome.
Sildenafil increases intracellular cyclic guanosine monophosphate levels in vascular smooth-muscle cells, thereby mediating vasorelaxation within 1 hour. In our patient, acute effects on hemodynamic variables were mild; better effects were achieved only with long-term treatment. Thus, mechanisms other than acute vasodilatation may be involved. Our most important finding may be the dramatic decrease of brain natriuretic peptide levels. In patients with pulmonary arterial hypertension, chronic elevation of pulmonary arterial pressure represents a consistently elevated afterload of the right heart, which ultimately leads to right-heart failure. Markedly elevated brain natriuretic peptide levels in patients with pulmonary arterial hypertension correlate with right ventricular dysfunction and have significant prognostic impact (9, 10) .
Conclusion: Phosphodiesterase type V inhibitors have beneficial effects in patients with pulmonary arterial hypertension related to systemic scleroderma and may provide a novel therapeutic approach for the Raynaud syndrome. (1) . The recurrence of type 1 diabetes mellitus, accompanied by antiglutamic acid decarboxylase antibody, can be observed even in a patient with a transplanted pancreas when the immunosuppression is insufficient (2) .
Stephan Rosenkranz
Objective: To investigate whether ␤-cell regeneration was occurring in the native pancreas of a patient receiving immunosuppressive therapy after simultaneous pancreas-kidney transplantation.
Case Report: A 32-year-old man who had a 19-year history of type 1 diabetes mellitus and end-stage renal failure received a simultaneous pancreas-kidney transplant in April 2000 at Osaka University Hospital, Osaka, Japan. The patient was C-peptide negative before transplantation but became independent of insulin therapy 42 days after transplantation. Since then, his hemoglobin A 1c level has been approximately 5%. Postoperative immunosuppressive therapy was based on a standard protocol: tacrolimus, mycophenolate mofetil, and prednisolone, with the induction of antilymphocyte globulin. There have been no signs of rejection since the transplantation. In March 2002, the patient had surgery for an abdominal incisional hernia under general anesthesia, and we had a chance to perform a laparoscopy-assisted native pancreas biopsy, using a method described elsewhere (3). Written informed consent was obtained, and the Ethics Committee of the Osaka University Medical School approved the study.
Pancreatic islets could be identified on immunohistochemical analyses, but they lacked insulin-positive cells, containing only glucagon-positive cells and somatostatin-positive cells (Figure, panel A) . This suggested that the pancreatic ␤-cells had been totally eliminated because of type 1 diabetes mellitus. However, outside the islets, many isolated, single insulin-positive cells could be observed (Figure,  panel B) . We also found that some of the isolated insulin-positive cells were also positive for glucagon (9 of 25), somatostatin (2 of 23), and cytokeratin (1 of 18) ( Figure, panels C and D) . These findings supported the possibility that the isolated insulin-positive cells may have been regenerating ␤-cells. Although we could not detect insulin-positive cells associated with the ducts, similar characteristics are often seen in newly formed ␤-cells in rodents (4) . In terms of immunologic reactions, no CD3-positive T cells or macrophages were seen around the patient's insulin-positive cells. Also, results of tests for serum antiglutamic acid decarboxylase antibody have been negative since the transplantation.
The percentage of insulin-positive cell area within the pancreas was 0.185% despite the lack of ␤-cells in the islets. Although we could not measure this variable before transplantation in this patient, we previously studied it in patients with type 1 diabetes mellitus (5) . When only the data derived from 37 patients with a disease duration of more than 10 years were selected, the mean percentage (ϮSD) of insulin-positive cell area within the pancreas was 0.046% Ϯ 0.066%. Although no quantitative data were available, the insulin-positive cells, if any, resided mostly in the islets, and no or very few single insulin-positive cells were found. However, the percentage of insulin-positive cell area was still much lower than the average value in the pancreases of 6 nondiabetic controls undergoing total gastrectomy for gastric cancer (mean [ϮSD], 0.992% Ϯ 0.476%) (Unpublished data).
Discussion: Our patient, who had type 1 diabetes mellitus and was once C-peptide negative, had many isolated insulin-producing cells in his pancreas that resembled regenerating ␤-cells. This finding is unusual. Similar investigations in more patients with type 1 diabetes mellitus who underwent simultaneous pancreas-kidney transplantation, pancreas transplantation alone, or islet transplantation may be warranted. Such investigations may help clarify the potential beneficial effect of immunosuppressive therapy on the possible regeneration of pancreatic ␤-cells in patients with type 1 diabetes mellitus. A. An islet, occupied with glucagon-positive cells, is shown in red. Original magnification, ϫ280. B. Some isolated insulin-positive cells (shown in green) are scattered outside the islets. Original magnification, ϫ280.
C. An insulin-positive cell is shown in green. Original magnification, ϫ560. D. The latter cell was also positive for somatostatin, shown in red. Original magnification, ϫ560. Immunohistochemical staining was used for all panels.
